While Tarceva offers significant benefits for certain patients, it is not effective for all types of cancer or for all patients with NSCLC or pancreatic cancer. The presence of specific genetic mutations is crucial for its effectiveness, and not all patients will have these mutations. Additionally, resistance to Tarceva can develop over time, necessitating alternative treatment options.
